-
Elders who ate sorbet before a meal ate more of the rest of their meal.
-
A very low energy diet followed by a weight maintenance program results in significant improvements in weight, obstructive sleep apnea, metabolic factors, and quality for at least a year.
-
A second NS3/4A protease inhibitor has been approved by the FDA for the treatment of chronic hepatitis C (HCV) genotype 1, joining the recently approved boceprevir (Victrelis). Telaprevir is marketed by Vertex Pharmaceuticals as Incivek.
-
-
Proton pump inhibitor use in clopidogrel-treated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.
-
-
In May of this year, German public health authorities reported a significant increase in the number of patients with diarrhea caused by a Shiga toxin-producing Escherichia coli (STEC), as well as of cases of hemolytic uremic syndrome (HUS).
-
The number of individuals with active tuberculosis in the United States reached an all-time low of 11,181 cases in 2010.
-
The National Health Service in Britain in 2007 elected to ban traditional white coats and other long-sleeved garments for physicians in the workplace (including long-sleeved blouses and shirts).
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
